---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000326"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T04:09:33.036213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Charles River Q4 revenue $1.10B (+21.5% YoY); DOJ subpoena on NHP supply; 2023 guidance below expectations

## Summary
- Q4 GAAP EPS $3.65, non-GAAP EPS $2.98; full-year GAAP EPS $9.48, non-GAAP EPS $11.12.
- Q4 organic revenue growth 18.8% led by DSA segment (+26.5% organic).
- Received DOJ subpoena on Cambodian NHP supply chain; voluntarily suspended shipments from Cambodia.
- 2023 guidance: reported revenue growth 1.5%-4.5%, organic 4.5%-7.5%; GAAP EPS $7.40-$8.60, non-GAAP $9.70-$10.90.
- NHP supply constraints expected to reduce 2023 revenue growth by 200-400 bps; higher tax and interest to pressure EPS.

## SEC filing metadata
- accession: 0001157523-23-000326
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/0001157523-23-000326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/a53335402.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000326
- JSON: https://secwatch.observer/filing/0001157523-23-000326.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000326.txt

## Key facts
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Fourth Quarter 2022 results: revenue $1.10 Billion, net income $187.4 million, EPS $3.65.
  - Period: Fourth Quarter 2022
  - Revenue: $1.10 Billion
  - Net income: $187.4 million
  - EPS: $3.65
  - Result: reported results
  source text: EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/0001157523-23-000326-index.htm
- Earnings Releases
  CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Full Year 2022 results: revenue $3.98 Billion, EPS $9.48.
  - Period: Full Year 2022
  - Revenue: $3.98 Billion
  - EPS: $9.48
  - Result: reported results
  source text: Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48 and Non-GAAP Earnings per Share of $11.12 – – Provides 2023 Guidance –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1100682/000115752323000326/0001157523-23-000326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.